CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $27.57M, above the global median of $18.73M
- FinancialsAltman Z-Score 2.17: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.03BCNY451.75M · vs all stocks (USD)
Revenue (TTM)
1.56BCNY232.83M · vs all stocks (USD)
Profit Margin
-25.01%Beta
0.1610xvs all stocks
52-Week Change
-5.91%vs all stocks
Market Capitalization
3.03BCNY451.75M · vs all stocks (USD)
Enterprise Value
3.08BCNY459.21M · vs all stocks (USD)
Forward P/E
9.13xPrice to Sales (TTM)
1.81xPrice to Book (MRQ)
1.32xEnterprise to Revenue
1.97xEnterprise to EBITDA
-58.84xGross Margin
57.39%Profit Margin
-25.01%Operating Margin
-19.90%Return on Assets (TTM)
-3.56%Return on Equity (TTM)
-16.39%Revenue (TTM)
1.56BCNY232.83M · vs all stocks (USD)
Revenue per Share (TTM)
2.00CNYUpdated Sep 21, 2026Quarterly Revenue Growth
-32.80%Gross Profit (TTM)
865.55MCNY129.25M · vs all stocks (USD)
EBITDA (TTM)
72.42MCNY10.81M · vs all stocks (USD)
Net Income (TTM)
-390.00MCNY-58.24M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-34.09%Operating Cash Flow (TTM)
150.29MCNY22.44M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
184.64MCNY27.57M · vs all stocks (USD)
5-Year Average Dividend Yield
0.44%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
82.82MCNYFY2025 · Dec 31, 2025Revenue
1.86BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
751.46MCNYFY2025 · Dec 31, 2025Gross Profit
1.11BCNYFY2025 · Dec 31, 2025Operating Income
-93.56MCNY-13.97M · vs all stocks (USD)
Pre-tax Income
-311.75MCNYFY2025 · Dec 31, 2025Income Tax Expense
23.59MCNYFY2025 · Dec 31, 2025Net Income
-335.34MCNYFY2025 · Dec 31, 2025EBIT
-288.37MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
72.42MCNYFY2025 · Dec 31, 2025Research & Development
84.27MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
778.69MCNYFY2025 · Dec 31, 2025Other Operating Expenses
31.46MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.77MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
23.37MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.4200CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.4200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
784.67MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
784.67MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-335.34MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
5.78MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-47.80MCNYFY2025 · Dec 31, 2025Free Cash Flow
-75.89MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
445.13MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-335.34MCNYFY2025 · Dec 31, 2025Other Non-cash Items
55.41MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
145.72MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
86.40MCNYFY2025 · Dec 31, 2025Capital Expenditures
-28.09MCNYFY2025 · Dec 31, 2025Sale of Investments
84.69KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-28.00MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
516.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-754.80MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-28.69MCNYFY2025 · Dec 31, 2025Other Financing Charges
-35.08MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-302.57MCNYFY2025 · Dec 31, 2025Shares Outstanding
791.93MSharesUpdated Sep 21, 2026Float Shares
580.25MSharesUpdated Sep 21, 2026% Held by Insiders
31.22%vs all stocks
% Held by Institutions
1.05%vs all stocks
Total Cash (MRQ)
470.45MCNY70.25M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.6000CNYUpdated Sep 21, 2026Total Debt (MRQ)
668.43MCNY99.82M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3049xCurrent Ratio (MRQ)
1.70xBook Value per Share (MRQ)
2.69CNYUpdated Sep 21, 2026Total Assets
3.44BCNY513.97M · vs all stocks (USD)
Total Current Assets
1.45BCNYFY2025 · Dec 31, 2025Total Liabilities
1.17BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.99BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
262.36MCNYFY2025 · Dec 31, 2025Total Current Liabilities
908.88MCNYFY2025 · Dec 31, 2025Cash
435.79MCNYFY2025 · Dec 31, 2025Cash Equivalents
11.35MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
447.13MCNYFY2025 · Dec 31, 2025Accounts Receivable
167.34MCNYFY2025 · Dec 31, 2025Inventory
546.90MCNYFY2025 · Dec 31, 2025Accounts Payable
102.99MCNYFY2025 · Dec 31, 2025Short-term Debt
602.10MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.53MCNYFY2025 · Dec 31, 2025Long-term Debt
102.50MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.20MCNYFY2025 · Dec 31, 2025Common Stock (Book)
791.93MCNYFY2025 · Dec 31, 2025Retained Earnings
424.42MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.27BCNY339.07M · vs all stocks (USD)
Treasury Stock
25.00MCNYFY2025 · Dec 31, 202552-Week Low
2.85CNYUpdated Sep 21, 202652-Week High
5.27CNYUpdated Sep 21, 202652-Week Change
-5.91%vs all stocks
Beta
0.1610xvs all stocks
50-Day MA
3.71CNYUpdated Sep 21, 2026200-Day MA
3.88CNYUpdated Sep 21, 2026Avg 10-Day Volume
22.40MSharesUpdated Sep 21, 2026Avg 30-Day Volume
46.45MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-0.5000CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.57Profit Margin: -0.25
Financial Health
Altman Z-Score 2.17: grey zoneSignificant
Altman Z-Score: 2.17
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $27.57M, above the global median of $18.73MNotable
Levered free cash flow (USD): 27,572,929.138Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nanjing Medlander Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jw Pharmaceutical Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Anhui Sunhere Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guanhao Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Clover Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tectonic Therapeutic Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Jiaoda Onlly Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Haisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow